{"version":"1.0","provider_name":"KFF Health News","provider_url":"https:\/\/kffhealthnews.org","author_name":"khnphilipg","author_url":"https:\/\/kffhealthnews.org\/news\/author\/khnphilipg\/","title":"Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only if Costly Gene Therapies Work - KFF Health News","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"PqRLWJRM8c\"><a href=\"https:\/\/kffhealthnews.org\/news\/article\/sickle-cell-disease-gene-therapy-medicaid-vertex-bluebird-bio\/\">Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only if Costly Gene Therapies Work<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kffhealthnews.org\/news\/article\/sickle-cell-disease-gene-therapy-medicaid-vertex-bluebird-bio\/embed\/#?secret=PqRLWJRM8c\" width=\"600\" height=\"338\" title=\"&#8220;Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only if Costly Gene Therapies Work&#8221; &#8212; KFF Health News\" data-secret=\"PqRLWJRM8c\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/kffhealthnews.org\/wp-content\/uploads\/sites\/2\/2026\/01\/Sickle-cell-drugs-05-lo.jpg","thumbnail_width":3500,"thumbnail_height":2333,"description":"The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With more expensive treatments on the horizon, the program \u2014 created by the Biden administration and continued under President Trump \u2014 could help Medicaid save money and treat more patients."}